Replimune Group (7R8) Price & Analysis

0 Followers

7R8 Stock Chart & Stats

€5.76

-€1.68(-22.60%)

At close: Jul 28 4:00 PM EDT

€5.76

-€1.68(-22.60%)

Day’s Range― - ―

52-Week Range€1.43 - €10.17

Previous CloseN/A

Volume0.00

Average Volume (3M)80.00

Market Cap

€816.03M

Enterprise Value€475.48

Total Cash (Recent Filing)€268.89M

Total Debt (Recent Filing)€111.59M

Price to Earnings (P/E)―

Beta0.05

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.38

Shares Outstanding84,026,070

10 Day Avg. Volume0

30 Day Avg. Volume80

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)4.27

Price to Sales (P/S)0.00

P/FCF Ratio-2.49

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€13.20

Price Target Upside129.21% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-2.11

Revenue Forecast (FY)€33.69M

Bulls Say, Bears Say

Bulls Say

Regulatory Momentum For RP1 BLAFDA acceptance of the RP1 BLA resubmission and an August 2, 2026 action date materially lower near-term regulatory uncertainty. For a clinical-stage biotech, a prioritized review creates a credible path to commercialization that could transform cash flow dynamics and partnership or licensing options over the next several months.

Favorable FDA Advisory Committee OutcomeA 10–3 advisory committee vote that trial efficacy is evaluable and clinically meaningful materially de-risks regulatory approval odds for RP1. This outcome strengthens the case for accelerated approval in a high unmet-need setting, supporting long-term commercial prospects and potential partner interest if the FDA follows the committee.

Proprietary Immulytic Platform & Multi-program PipelineA proprietary platform with multiple development-stage programs provides durable strategic optionality: it enables a pipeline approach, potential combination strategies, and multiple shots on goal. If RP1 succeeds commercially, the platform could be leveraged to expand indications or out-license/develop follow-on assets, supporting long-term growth.

Bears Say

No Revenue; Widening Net LossesPersistent absence of product revenue combined with steeply widening net losses reflects a classic pre-commercial biotech burn profile. Without near-term commercial sales, continued losses materially increase reliance on capital markets; sustained negative earnings undermine financial resilience absent successful approval or partnership milestones.

Accelerating Negative Operating Cash FlowDeepening negative operating cash flow signals accelerating cash burn and shortens runway unless offset by financing or revenue. This structural cash generation weakness forces frequent capital raises, elevates dilution risk, and limits the company's ability to scale commercialization or invest in additional trials without external funding.

Eroding Equity Base Increases Dilution RiskA sharply reduced equity base weakens the capital cushion and implies prior financings and losses have materially diluted shareholders. This deterioration increases the likelihood of further dilutive financings to fund operations, creating persistent shareholder dilution risk and constraining strategic flexibility over the medium term.

Replimune Group News

Walmart downgraded, Palantir upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

9h ago

AIP

Replimune upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Replimune (REPL) to Outperform from Market Perform with a price target of $17, up from $11....

13h ago

REPL

These 2 Stocks Just Broke Out — and They Could Go Higher, Say Analysts

Past performance may not guarantee future results, but it can still provide valuable clues. When a stock suddenly...

2d ago

AXTI

REPL

Midday Fly By: Apple sinks after guidance, Amazon’s AWS powers beat

The major averages were somewhat higher near noon as traders weighed earnings from Apple and Amazon. While Amazon...

4d ago

BSX

Why Is Replimune (REPL) Stock Up Today?

Replimune stock rallied on Friday thanks to an FDA update that acted as a catalyst for analyst upgrades. ...

4d ago

REPL

Roblox downgraded, Quanta Services upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4d ago

BSX

Morning Movers: Amazon jumps after quarterly results while Apple slips

Stock futures are pointing modestly higher ahead of Friday’s opening bell as investors look to build on the...

4d ago

CVX

ETN

Piper upgrades Replimune to Overweight on better odds of RP1 approval

As previously reported, Piper Sandler analyst Allison Bratzel upgraded Replimune (REPL) to Overweight from Neutral with a price...

4d ago

REPL

Replimune upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Replimune (REPL) to Overweight from Neutral with a $14 price target Published first on TheFly...

4d ago

REPL

Replimune price target raised to $12 from $9 at Wedbush

Wedbush raised the firm’s price target on Replimune (REPL) to $12 from $9 and keeps a Neutral rating...

4d ago

REPL

Why is Biotech Stock Replimune (REPL) Soaring Over 120% Today?

Shares in biotechnology company Replimune ($REPL) soared over 120% in pre-market trading today after U.S. regulators gave the...

4d ago

BMY

REPL

Replimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Cantor Fitzgerald upgraded Replimune (REPL) to Overweight from Neutral without a price target citing the FDA panel vote...

5d ago

REPL

Replimune confirms FDA AdCom voted in favor of experimental melanoma treatment

The company states: “Replimune (REPL) announced the outcome of today’s meeting of the U.S. Food and Drug Administration’s...

5d ago

REPL

‘Blue Sky’ Ahead? J.P. Morgan Picks 2 Stocks to Buy for the Rest of 2026

As the second half of 2026 gets rolling, it’s a good time to step back and take a...

26d ago

ALGT

REPL

7R8 FAQ

What was Replimune Group Inc’s price range in the past 12 months?

Replimune Group Inc lowest stock price was €1.43 and its highest was €10.16 in the past 12 months.

What is Replimune Group Inc’s market cap?

Replimune Group Inc’s market cap is €816.03M.

When is Replimune Group Inc’s upcoming earnings report date?

Replimune Group Inc’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.

How were Replimune Group Inc’s earnings last quarter?

Replimune Group Inc released its earnings results on Jun 29, 2026. The company reported -€0.66 earnings per share for the quarter, missing the consensus estimate of -€0.574 by -€0.086.

Is Replimune Group Inc overvalued?

According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Replimune Group Inc pay dividends?

Replimune Group Inc does not currently pay dividends.

What is Replimune Group Inc’s EPS estimate?

Replimune Group Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Replimune Group Inc have?

Replimune Group Inc has 84,026,070 shares outstanding.

What happened to Replimune Group Inc’s price movement after its last earnings report?

Replimune Group Inc reported an EPS of -€0.66 in its last earnings report, missing expectations of -€0.574. Following the earnings report the stock price went up 13.931%.

Which hedge fund is a major shareholder of Replimune Group Inc?

Currently, no hedge funds are holding shares in DE:7R8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Replimune Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-39.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Replimune Group Inc

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Replimune Group (7R8) Earnings & Revenues

Historic Earnings Reports

7R8 Stock 12 Month Forecast

Average Price Target

€13.20

▲(129.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","8":"€8","15":"€15","4.5":"€4.5","11.5":"€11.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.766019459999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€14.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.202558576,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.42307256,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.5,8,11.5,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.625,5.40507842,6.185156839999999,6.96523526,7.74531368,8.5253921,9.30547052,10.085548939999999,10.86562736,11.64570578,12.425784199999999,13.20586262,13.98594104,{"y":14.766019459999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.625,5.284812198153846,5.944624396307692,6.604436594461538,7.264248792615384,7.92406099076923,8.583873188923077,9.243685387076923,9.903497585230769,10.563309783384614,11.22312198153846,11.882934179692306,12.542746377846154,{"y":13.202558576,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.625,5.071005581538461,5.517011163076923,5.963016744615384,6.4090223261538455,6.855027907692307,7.301033489230769,7.7470390707692305,8.193044652307691,8.639050233846152,9.085055815384614,9.531061396923075,9.977066978461538,{"y":10.42307256,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.336,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.625,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >